San Cristóbal de La Laguna
San Cristóbal de La Laguna
San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain44 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-10-09 | NCT03701334 | |
| Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis | Endometrioma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neurologic Manifestations, Pain, Pathological Conditions, Signs and Symptoms, Pelvic Pain, Signs and Symptoms, Urogenital Diseases, endometriosis, female reproductive system disorder | Recruiting | Not applicable | 2026-10-08 | NCT06955221 | |
| Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Liver Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, breast disorder, breast neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, differentiated thyroid carcinoma, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gastric cancer, gastric neoplasm, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck cancer, hepatocellular carcinoma, intestinal disorder, kidney cancer, kidney disorder, liver disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, rectal disorder, renal cell carcinoma, respiratory system disorder, respiratory tract neoplasm, skin disorder, stomach disorder, transitional cell carcinoma, triple-negative breast carcinoma, urinary system disorder, urothelial carcinoma, uterine disorder | Active, not recruiting | Phase 1 | 2026-10-01 | NCT03170960 | |
| Inter-Device Concordance of Plantar Thermal Asymmetry Measurement (HIK-DM-2026) | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease | Recruiting | Not stated | 2026-09-30 | NCT07463456 | |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 3 | 2026-09-24 | NCT06136559 | |
| A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-09-24 | NCT05552976 | |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica | Skin and Connective Tissue Diseases, connective tissue disorder, muscle tissue disorder, musculoskeletal system disorder, polymyalgia rheumatica, rheumatic disorder | Recruiting | Phase 4 | 2026-09-22 | NCT07286214 | |
| ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, injury, neoplasm, radiation injury, skin disorder | Recruiting | Not applicable | 2026-09-17 | NCT04889924 | |
| A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)] | Skin and Connective Tissue Diseases, connective tissue disorder, dermatomyositis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Recruiting | Phase 3 | 2026-09-15 | NCT05895786 | |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Nutritional and Metabolic Diseases, autoimmune disease, diabetes mellitus, endocrine system disorder, glucose metabolism disease, immune system disorder, metabolic disease, type 1 diabetes mellitus | Recruiting | Phase 3 | 2026-09-14 | NCT07088068 | |
| A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Infarction, Lipid Metabolism Disorders, Necrosis, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, arteriosclerosis disorder, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, coronary artery disorder, coronary stenosis, heart disorder, hyperlipidemia, ischemic disease, metabolic disease, myocardial infarction, myocardial ischemia, nervous system disorder, stroke disorder, vascular disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT05739383 | |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, autoimmune disease, connective tissue disorder, glomerulonephritis, immune system disorder, kidney disorder, lupus nephritis, nephritis, systemic lupus erythematosus, urinary system disorder | Active, not recruiting | Phase 3 | 2026-08-21 | NCT05126277 | |
| A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | Chronic Disease, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Subcutaneous Emphysema, alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease, hereditary disease, liver disorder, lung disorder, obstructive lung disease, pulmonary emphysema, respiratory system disorder | Recruiting | Phase 3 | 2026-08-11 | NCT07555483 | |
| Inclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder | Active, not recruiting | Not stated | 2026-08-07 | NCT06958315 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-07-22 | NCT05253651 | |
| A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04975308 | |
| Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis | cardiovascular disorder, endocarditis, heart disorder, infective endocarditis | Recruiting | Phase 4 | 2026-07-07 | NCT05398679 | |
| Medical Device for Sustained Remission in Rheumatoid Arthritis Treated With Biological Therapy | Skin and Connective Tissue Diseases, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, immune system disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis | Recruiting | Not applicable | 2026-07-01 | NCT07678112 | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-06-25 | NCT04090736 | |
| Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Phase 2 | 2026-06-04 | NCT06856213 | |
| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T-cell non-Hodgkin lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mature T-cell and NK-cell non-Hodgkin lymphoma, neoplasm | Recruiting | Not stated | 2026-06-03 | NCT07624838 | |
| Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER) | Arterial Occlusive Diseases, Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arteriosclerosis disorder, arthritic joint disease, arthropathy, atherosclerosis, autoimmune disease, bone disorder, brain disorder, cardiovascular disorder, carotid artery disorder, central nervous system disorder, cerebrovascular disorder, connective tissue disorder, immune system disorder, musculoskeletal system disorder, nervous system disorder, psoriasis, psoriatic arthritis, rheumatic disorder, rheumatoid arthritis, skin disorder, spondylitis, systemic lupus erythematosus, vascular disorder, vertebral column disorder | Recruiting | Phase 4 | 2026-05-28 | NCT07611747 | |
| Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters | Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, hypertension, pregnancy-induced, preeclampsia, pregnancy disorder | Recruiting | Not stated | 2026-05-15 | NCT06716242 | |
| Impact of IBD Activity on Frailty in Patients Over 60 Years | inflammatory bowel disease | Recruiting | Not stated | 2026-05-07 | NCT06844318 |